

U.S.S.N. 09/534,717

2

Group Art Unit: 1647

In the claims:

Please amend the claims as follows:

Claims 1-8. (Canceled)

9. (Previously presented) An isolated human antibody, or antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a K_d of 1×10^{-10} M or less and a k_{off} rate constant of $1 \times 10^{-3} \text{ s}^{-1}$ or less, as determined by surface plasmon resonance.

10. (Previously presented) The isolated human antibody of claim 9, or an antigen-binding portion thereof, which dissociates from human IL-12 with a k_{off} rate constant of $1 \times 10^{-4} \text{ s}^{-1}$ or less.

11. (Previously presented) The isolated human antibody of claim 9, or an antigen-binding portion thereof, which dissociates from human IL-12 with a k_{off} rate constant of $1 \times 10^{-5} \text{ s}^{-1}$ or less.

12. (Previously presented) The neutralizing antibody of claim 143, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-9} M or less.

13. (Previously presented) The neutralizing antibody of claim 143, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-10} M or less.

14. (Previously presented) The neutralizing antibody of claim 143, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-11} M or less.

Claims 15-40. (Canceled)

U.S.S.N. 09/534,717

3

Group Art Unit: 1647

41. **(Original)** An isolated human antibody, or an antigen-binding portion thereof, which
- a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-9} M or less;
 - b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25; and
 - c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26.
42. **(Original)** The isolated human antibody, or an antigen-binding portion thereof, of claim 41 which further has a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27; and a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28.
43. **(Original)** The isolated human antibody, or an antigen-binding portion thereof, of claim 41 which further has a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29; and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30.
44. **(Original)** An isolated human antibody, or an antigen-binding portion thereof, having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 32.
45. **(Original)** The isolated human antibody of claim 44, comprising a heavy chain constant region selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions.
46. **(Original)** The isolated human antibody of claim 45, wherein the antibody heavy chain constant region is IgG1.
47. **(Original)** The isolated human antibody of claim 44, which is a Fab fragment.

U.S.S.N. 09/534,717

4

Group Art Unit: 1647

48. (Original) The isolated human antibody of claim 44, which is a F(ab')₂ fragment.

49. (Original) The isolated human antibody of claim 44, which is a single chain Fv fragment.

Claims 50-87. (Canceled)

88. (Currently amended) A pharmaceutical composition comprising the antibody or an antigen binding portion thereof, of claim 9, 41, ~~44~~, 151, 153, 164, 167, 168, ~~172~~, ~~or 183~~, ~~or 184~~, and a pharmaceutically acceptable carrier.

Claims 89-90 (Canceled)

91. (Currently amended) The pharmaceutical composition of claim ~~89~~ 88, ~~wherein the further comprising an additional therapeutic agent, is selected from the group consisting of budenoside, ; corticosteroids, cyclosporin, sulfasalazine, aminosaliclates, 6-mercaptopurine, azathioprine, metronidazole, ; mesalamine, olsalazine, balsalazide, antioxidants, ; antibodies to IL-1 receptor, anti-IL-1 β monoclonal antibodies, anti-IL-6 monoclonal antibodies, ;, pyridinyl-imidazole compounds, anti-TNF antibodies, or fragments thereof, and anti-LT antibodies, anti-IL-1 antibodies, anti-IL-2 antibodies, anti-IL-6 antibodies, anti-IL-7 antibodies, anti-IL-8 antibodies, anti-IL-15 antibodies, anti-IL-16 antibodies, anti-IL-18 antibodies, anti-EMAP-II antibodies, anti-GM-CSF antibodies, anti-FGF antibodies, anti-PDGF antibodies, anti-CD2 antibodies, anti-CD3 antibodies, anti-CD4 antibodies, anti-CD8 antibodies, anti-CD25 antibodies, anti-CD28 antibodies, anti-CD30 antibodies, anti-CD40 antibodies, anti-CD45 antibodies, anti-CD69 antibodies, anti-CD80 (B7.1) antibodies, anti-CD86 (B7.2) antibodies, anti-CD90 antibodies, ;, methotrexate, FK506, rapamycin, mycophenolate mofetil, leflunomide, non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen, corticosteroids, prednisolone, ; sulfasalazine, azathioprine, 6-mercaptopurines, ; soluble p55 TNF receptor, soluble p75 TNF receptor, sIL-1RI, sIL-1RII, sIL-6R, ~~sIL-13~~, antiinflammatory cytokines, IL-4, IL-10, IL-11, IL-13, and TGF β .~~

Claims 92-141. (Canceled)

U.S.S.N. 09/534,717

5

Group Art Unit: 1647

142. **(Previously presented)** The isolated human antibody, or antigen-binding portion thereof, of claim 9, which is a recombinant antibody, or antigen-binding portion thereof.

143. **(Previously presented)** The isolated human antibody of any one of claims 9 to 11, wherein the antibody is a neutralizing antibody.

144. **(Previously presented)** The neutralizing antibody of claim 143, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an IC_{50} of 1×10^{-7} M or less.

145. **(Previously presented)** The neutralizing antibody of claim 143, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-8} M or less.

146. **(Previously presented)** The neutralizing antibody of claim 143, or an antigen-binding portion thereof, which inhibits human IFN γ production with an IC_{50} of 1×10^{-10} M or less.

147. **(Previously presented)** The neutralizing antibody of claim 143, or an antigen-binding portion thereof, which inhibits human IFN γ production with an IC_{50} of 1×10^{-11} M or less.

148. **(Previously presented)** The neutralizing antibody of claim 143, or an antigen-binding portion thereof, which inhibits human IFN γ production with an IC_{50} of 5×10^{-12} M or less.

149. **(Previously presented)** The isolated human antibody, or antigen-binding portion thereof, of claim 41, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-10} M or less.

U.S.S.N. 09/534,717

6

Group Art Unit: 1647

150. **(Previously presented)** The isolated human antibody, or antigen-binding portion thereof, of claim 41, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-11} M or less.
151. **(Previously presented)** An isolated human antibody, or an antigen-binding portion thereof, which dissociates from human IL-12 with a K_d of 1×10^{-10} M or less and binds to an epitope on the p40 subunit of human IL-12.
152. **(Previously presented)** The isolated human antibody of claim 151, which neutralizes the activity of human IL-12.
153. **(Previously presented)** A neutralizing isolated human antibody, or antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a k_{off} rate constant of $1 \times 10^{-3} s^{-1}$ or less, as determined by surface plasmon resonance.
154. **(Previously presented)** The neutralizing isolated human antibody of claim 153, or an antigen-binding portion thereof, which dissociates from human IL-12 with a k_{off} rate constant of $1 \times 10^{-4} s^{-1}$.
155. **(Previously presented)** The neutralizing isolated human antibody of claim 153, or an antigen-binding portion thereof, which dissociates from human IL-12 with a k_{off} rate constant of $1 \times 10^{-5} s^{-1}$ or less.
156. **(Previously presented)** The neutralizing isolated human antibody of any one of claims 153 to 155, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-7} M or less.
157. **(Previously presented)** The neutralizing isolated human antibody of any one of claims 153 to 155, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-8} M or less.

U.S.S.N. 09/534,717

7

Group Art Unit: 1647

158. **(Previously presented)** The neutralizing isolated human antibody of any one of claims 153 to 155, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-9} M or less.

159. **(Previously presented)** The neutralizing isolated human antibody of any one of claims 153 to 155, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-10} M or less.

160. **(Previously presented)** The neutralizing isolated human antibody of any one of claims 153 to 155, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-11} M or less.

161. **(Previously presented)** The neutralizing isolated human antibody of any one of claims 153 to 155, or an antigen-binding portion thereof, which inhibits human $IFN\gamma$ production with an IC_{50} of 1×10^{-10} M or less.

162. **(Previously presented)** The neutralizing isolated human antibody of any one of claims 153 to 155, or an antigen-binding portion thereof, which inhibits human $IFN\gamma$ production with an IC_{50} of 1×10^{-11} M or less.

163. **(Previously presented)** The neutralizing isolated human antibody of any one of claims 153 to 155, or an antigen-binding portion thereof, which inhibits human $IFN\gamma$ production with an IC_{50} of 5×10^{-12} M or less.

164. **(Previously presented)** An isolated human antibody, or an antigen-binding portion thereof, which

a) dissociates from human IL-12 with a k_{off} rate constant of $1 \times 10^{-3} s^{-1}$ or less, as determined by surface plasmon resonance;

b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25; and

c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26.

U.S.S.N. 09/534,717

8

Group Art Unit: 1647

165. **(Previously presented)** The isolated human antibody of claim 164, or an antigen-binding portion thereof, which dissociates from human IL-12 with a k_{off} rate constant of $1 \times 10^{-4} \text{ s}^{-1}$ or less.

166. **(Previously presented)** The isolated human antibody of claim 164, or an antigen-binding portion thereof, which dissociates from human IL-12 with a k_{off} rate constant of $1 \times 10^{-5} \text{ s}^{-1}$ or less.

167. **(Previously presented)** An isolated human antibody, or antigen-binding portion thereof, that binds to human IL-12 and comprises:
a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 26; and
a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 25.

168. **(Previously presented)** An isolated human antibody, or an antigen-binding portion thereof, with a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 26, and with a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 25.

169. **(Previously presented)** The isolated human antibody, or an antigen-binding portion thereof, of claim 168, wherein the LCVR further has a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 28 and the HCVR further has a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 27.

170. **(Previously presented)** The isolated human antibody, or an antigen-binding portion thereof, of claim 169, wherein the LCVR further has CDR1 domain comprising the amino acid sequence of SEQ ID NO: 30 and the HCVR has a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 29.

171. **(Previously presented)** A pharmaceutical composition comprising an antibody or an antigen binding portion thereof, and a pharmaceutically acceptable carrier, wherein the antibody comprises:

U.S.S.N. 09/534,717

9

Group Art Unit: 1647

a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 26; and
a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 25.

172. **(Previously presented)** An isolated human antibody that binds human IL-12 and is the antibody J695, or an antigen binding portion thereof.

173. **(Previously presented)** A pharmaceutical composition comprising the isolated human antibody of claim 172 and a pharmaceutically acceptable carrier.

Claims 174-182. **(Canceled)**

183. **(Previously presented)** An isolated human antibody, or antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a K_d of 1.34×10^{-10} M or less, and neutralizes human IL-12.

184. **(Previously presented)** The isolated human antibody of claim 183, or an antigen-binding portion thereof, which dissociates from human IL-12 with a K_d of 9.74×10^{-11} M or less.

185. **(Previously presented)** The isolated human antibody, or antigen-binding portion thereof, of claims 183 or 184, which is a recombinant antibody, or antigen-binding portion thereof.

186. **(Previously presented)** The isolated human antibody of claim 185, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-7} M or less.

187. **(Previously presented)** The isolated human antibody of claim 185, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-8} M or less

U.S.S.N. 09/534,717

10

Group Art Unit: 1647

188. (Previously presented) The isolated human antibody of claim 185, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-9} M or less.

189. (Previously presented) The isolated human antibody of claim 185, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-10} M or less.

190. (Previously presented) The isolated human antibody of claim 185, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-11} M or less.

191. (Previously presented) The isolated human antibody of claim 185, or an antigen-binding portion thereof, which inhibits human $IFN\gamma$ production with an IC_{50} of 1×10^{-10} M or less.

192. (Previously presented) The isolated human antibody of claim 185, or an antigen-binding portion thereof, which inhibits human $IFN\gamma$ production with an IC_{50} of 1×10^{-11} M or less.

193. (Previously presented) The isolated human antibody of claim 185, or an antigen-binding portion thereof, which inhibits human $IFN\gamma$ production with an IC_{50} of 5×10^{-12} M or less.

194. (Previously presented) The isolated human antibody of claim 185, or an antigen-binding portion thereof, which inhibits IL-12 binding to its receptor in an IL-12 receptor binding assay (RBA) with an IC_{50} of 1×10^{-9} M or less.

195. (Previously presented) The isolated human antibody of claim 185, or an antigen-binding portion thereof, which inhibits IL-12 binding to its receptor in an IL-12 receptor binding assay (RBA) with an IC_{50} of 1×10^{-10} M or less.

196. (Previously presented) The isolated human antibody of claim 185, or an antigen-binding portion thereof, which inhibits IL-12 binding to its receptor in an IL-12 receptor binding assay (RBA) with an IC_{50} of 1×10^{-11} M or less.

U.S.S.N. 09/534,717

11

Group Art Unit: 1647

197. (New) The pharmaceutical composition of claim 88, further comprising an additional therapeutic agent selected from the group consisting of anti-IL-1 antibodies, anti-IL-2 antibodies, anti-IL-6 antibodies, anti-IL-7 antibodies, anti-IL-8 antibodies, anti-IL-15 antibodies, anti-IL-16 antibodies, anti-IL-18 antibodies, anti-EMAP-II antibodies, anti-GM-CSF antibodies, anti-FGF antibodies, anti-PDGF antibodies, anti-CD2 antibodies, anti-CD3 antibodies, anti-CD4 antibodies, anti-CD8 antibodies, anti-CD25 antibodies, anti-CD28 antibodies, anti-CD30 antibodies, anti-CD40 antibodies, anti-CD45 antibodies, anti-CD69 antibodies, anti-CD80 (B7.1) antibodies, anti-CD86 (B7.2) antibodies, and anti-CD90 antibodies.

198. (New) The pharmaceutical composition of claim 88, further comprising an additional therapeutic agent selected from the group consisting of methotrexate, FK506, rapamycin, mycophenolate mofetil, leflunomide, non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen, prednisolone, 6-mercaptopurines, soluble p55 TNF receptor, soluble p75 TNF receptor, sIL-1RI, sIL-1RII, sIL-6R, sIL-13, antiinflammatory cytokines, IL-4, IL-10, IL-11, IL-13, TGF β , Vx740, anti-P7s, p-selectin glycoprotein ligand (PSGL), p75TNFRlgG (EnbrelTM), p55TNFRlgG (LenerceptTM), pyridinyl-imidazole compounds, anti-gp39 antibodies, anti-CD40L antibodies, methotrexate, cytokine suppressive anti-inflammatory drugs (CSAIDs), leflunomide, MP, mesalazine, chloroquine/hydroxychloroquine, pencillamine, aurothiomalate, cochlincine, salbutamol, terbutaline, salmeterol, theophylline, aminophylline, cromoglycate, nedocromil, ketotifen, ipratropium, and oxitropium.

199. (New) The pharmaceutical composition of claim 88, further comprising an additional therapeutic agent selected from the group consisting of anti-IRAK antibodies, anti-NIK antibodies, anti-IKK antibodies, anti-p38 antibodies, D2E7, cA2 (RemicadeTM), CDP 571, 5-aminosalicylic acid, TNFR-Ig constructs, dexamethasone, aminosalicylic acid, IL-1ra, methylprednisolone, cyclophosphamide, methotrexate, 4-aminopyridine, tizanidine, interferon- β 1a (AvonexTM), interferon- β 1b (BetaseronTM), Copolymer 1 (Cop-1; CopaxoneTM), hyperbaric oxygen, clabribine, anti-EMAP-II antibodies, IFN β 1a, IFN β 1b, and IL-1.

200. (New) A pharmaceutical composition comprising the antibody or an antigen binding portion thereof of claim 143, and a pharmaceutically acceptable carrier.

U.S.S.N. 09/534,717

12

Group Art Unit: 1647

201. (New) The pharmaceutical composition of claim 200, further comprising an additional therapeutic agent selected from the group consisting of budenoside, corticosteroids, cyclosporin, sulfasalazine, aminosaliclates, 6-mercaptopurine, azathioprine, metronidazole, mesalamine, olsalazine, balsalazide, antioxidants, antibodies to IL-1 receptor, anti-IL-1 β monoclonal antibodies, anti-IL-6 monoclonal antibodies, pyridinyl-imidazole compounds, anti-TNF antibodies, or fragments thereof, and anti-LT antibodies.

202. (New) The pharmaceutical composition of claim 200, further comprising an additional therapeutic agent selected from the group consisting of anti-IL-1 antibodies, anti-IL-2 antibodies, anti-IL-6 antibodies, anti-IL-7 antibodies, anti-IL-8 antibodies, anti-IL-15 antibodies, anti-IL-16 antibodies, anti-IL-18 antibodies, anti-EMAP-II antibodies, anti-GM-CSF antibodies, anti-FGF antibodies, anti-PDGF antibodies, anti-CD2 antibodies, anti-CD3 antibodies, anti-CD4 antibodies, anti-CD8 antibodies, anti-CD25 antibodies, anti-CD28 antibodies, anti-CD30 antibodies, anti-CD40 antibodies, anti-CD45 antibodies, anti-CD69 antibodies, anti-CD80 (B7.1) antibodies, anti-CD86 (B7.2) antibodies, and anti-CD90 antibodies.

203. (New) The pharmaceutical composition of claim 200, further comprising an additional therapeutic agent selected from the group consisting of methotrexate, FK506, rapamycin, mycophenolate mofetil, leflunomide, non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen, prednisolone, 6-mercaptopurines, soluble p55 TNF receptor, soluble p75 TNF receptor, sIL-1RI, sIL-1RII, sIL-6R, sIL-13, antiinflammatory cytokines, IL-4, IL-10, IL-11, IL-13, TGF β , Vx740, anti-P7s, p-selectin glycoprotein ligand (PSGL), p75TNFRIgG (EnbrelTM), p55TNFRIgG (LenerceptTM), pyridinyl-imidazole compounds, anti-gp39 antibodies, anti-CD40L antibodies, methotrexate, cytokine suppressive anti-inflammatory drugs (CSAIDs), leflunomide, MP, mesalazine, chloroquine/hydroxychloroquine, pencillamine, aurothiomalate, cochicine, salbutamol, terbutaline, salmeterol, theophylline, aminophylline, cromoglycate, nedocromil, ketotifen, ipratropium, and oxitropium.

204. (New) The pharmaceutical composition of claim 200, further comprising an additional therapeutic agent selected from the group consisting of anti-IRAK antibodies, anti-NIK antibodies, anti-IKK antibodies, anti-p38 antibodies, D2E7, cA2 (RemicadeTM), CDP 571, 5-aminosalicylic acid, TNFR-Ig constructs, dexamethasone, aminosaliclic acid, IL-1ra, methylprednisolone, cyclophosphamide, methotrexate, 4-aminopyridine,

U.S.S.N. 09/534,717

13

Group Art Unit: 1647

tizanidine, interferon- β 1a (AvonexTM), interferon- β 1b (BetaseronTM), Copolymer 1 (Cop-1; CopaxoneTM), hyperbaric oxygen, clabribine, anti- EMAP-II antibodies, IFN β 1a, IFN β 1b, and IL-1.

205. (New) The isolated human antibody of claim 9, or an antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a K_d of 1.34×10^{-10} M or less.

206. (New) The isolated human antibody of claim 9, or an antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a K_d of 9.74×10^{-11} M or less.